Navigation Links
Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007
Date:11/7/2007

s before

changes in non-cash operating working

capital items 11.2 7.8 44.3%

Consolidated Results for the 9-month periods ended September 30

(unaudited)

2007 2006 Change

Revenues 272.0 223.6 21.7%

Gross Margin (1) 91.8 66.1 38.9%

33.7% 29.6%

EBITDA (2) 46.9 34.0 37.7%

17.2% 15.2%

Net Earnings 25.0 19.6 27.4%

Net earnings per share

Basic 0.81 0.65

Diluted 0.76 0.60

Cash flow from operating activities before

changes in non-cash operating working

capital items 28.5 23.4 21.5%

Consolidated Results for the 3-month periods ended September 30

(unaudited)

2007 2006 Change

Health & Nutrition

------------------

Revenues 50.9 28.3 80.0%

EBITDA (2) 15.3 7.3 109.5%

30.0% 25.8%

Active Ingredients & Speciality Chemicals

-----------------------------------------

Revenues 50.0 45.0 11.1%

EBITDA (2) 4.0 3.7 6.7%

7.9% 8.2%

Consolidated Results for the 9-month periods ended September 30

(unaudited)


'/>"/>

SOURCE Atrium Innovations Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Atrium Innovations Announces Management Changes
2. Atrium Innovations to Hold 2007 Third Quarter Financial Results Conference Call and Webcast on November 8
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
...  Frank A. Critz, M.D., founder and medical director of Radiotherapy ... welcome this April when he returns to Fulton, Miss.  for ... will be April 14, 2012 at the Holiday Inn Express ... until 3 p.m., and lunch will be served. ...
... 20, 2012 The American College of Radiology (ACR) ... Donald P. Rosen, MD, chief executive officer of ACR ... research organization (CRO) and for-profit subsidiary of the ACR. ... of experience in radiology, including contract research and business ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Virus (HIV) infections, announced today that it has ... pursuant to which the Company has agreed to ... stock at an aggregate purchase price of approximately ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™ 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... Gene expression is the process whereby the genetic ... products, such as proteins, which have numerous different ... as an important intermediary during gene expression, by ... molecular mechanisms involved in manufacturing proteins. , ... mRNA molecules present in an organism at a ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... protein kinase is an essential regulator of cytoskeletal ... whether Rho kinase regulates microtubule remodeling or the ... remains unclear. By using the ROCK inhibitor, Y-27632, ... colleagues from First Affiliated Hospital of Jinan University ...
... know about MyPyramid the triangle depicting how many servings ... - but who knows about MyPlate - the circle showing ... 2011 by the United States Department of Agriculture (USDA) to ... a simple, colorful icon that prompts us to think about ...
... cell-based gene therapy holds promise for the treatment of devastating ... approach have been unclear. In a study online December 26th ... published by Cell Press, researchers evaluated a patient with a ... years after he had undergone a gene therapy procedure as ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... Reacts with an early ... infection 3 hours post-infection exhibiting ... reaches peak intensity between 6-24 ... extremely intense coarsely granular staining. ...
Biology Products: